- Record: found
- Abstract: found
- Article: not found
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Faye M Johnson
1 ,
B Nebiyou Bekele ,
Lei Feng ,
Ignacio Wistuba ,
Xi Ming Tang ,
Hai T Tran ,
Jeremy J Erasmus ,
Li-Ling Hwang ,
Naoko Takebe ,
George R Blumenschein ,
Scott M Lippman ,
David J Stewart
Oct 20 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Src family kinases (SFKs) promote cancer progression and are commonly expressed in non-small-cell lung cancer (NSCLC), but the clinical effects of SFK inhibition in NSCLC are unknown. We conducted a phase II trial of the SFK inhibitor dasatinib for advanced NSCLC. We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a response to dasatinib.